Michael Redman: former CEO Oncolix, Inc. 2006 - May 2019 13 years...now, Executive VP and COO Genprex, Inc. Jan 2020 - Present, Texas
Genprex is a cancer and gene therapy company. The company's lead product, Oncoprex, is in Phase 2 clinical trials. Hmmm, ONCOprex...Oncolix.
Oncoprex (Genprex) has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells.
The Company‘s (Oncolix) Prolanta is a genetically modified form of human prolactin, a hormone associated with various types of cancers. Prolanta is designed to bind to the prolactin receptor on cells to block the effects of human prolactin. Human prolactin has documented to cause cancer cell proliferation by interacting with cancer cells.
Does Oncoprex or REQORSA use any prolactin-based research from Oncolix in their matrices? There isn't much of a description given on the Genprex site.
May 6 2021 deadline for filing has passed for Oncolix. No Board or business leaders mentioned as active for the company.
